Document Detail

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.
MedLine Citation:
PMID:  17325848     Owner:  NLM     Status:  MEDLINE    
Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at our institution. This prompted us to undertake a retrospective, multicenter study to analyse the characteristics of patients who exhibited ONJ and to define the frequency of ONJ in multiple myeloma (MM). We identified 35 cases in Gruppo Italiano Studio Linfomi centers during the period 2002 - 05. The median time from cancer diagnosis to the clinical onset of ONJ was 70 months. In these 35 cases of ONJ, 24 appeared 20 - 60 months after starting BP treatment. The time for the onset of ONJ was significantly shorter for patients treated with zoledronic acid alone than for those treated with pamidronate followed by zoledronic acid. The frequency of ONJ in the MM group during the study period was 1.9%, although the nature of the present study may have resulted in an underestimation of ONJ cases. Our analysis strongly suggested an association between the use of BP and the occurrence of ONJ, although we were unable to identify any definite risk factors with a retrospective study. The most frequently ONJ-associated clinical characteristics were chemotherapy treatment, steroid treatment, advanced age, female sex, anemia, parodonthopaties/dental procedures and thalidomide (in the case of MM patients).
Samantha Pozzi; Raffaella Marcheselli; Stefano Sacchi; Luca Baldini; Francesco Angrilli; Elsa Pennese; Giovanni Quarta; Caterina Stelitano; Giuseppe Caparotti; Stefano Luminari; Pellegrino Musto; Donato Natale; Chiara Broglia; Angela Cuoghi; Daniele Dini; Paolo Di Tonno; Giovanna Leonardi; Graziano Pianezze; Vincenzo Pitini; Giuseppe Polimeno; Luisa Ponchio; Luciano Masini; Maurizio Musso; Mauro Spriano; Giuseppe Pollastri;
Related Documents :
11398938 - Acquired inflammatory white matter disease.
8108668 - Coexisting kappa light chain multiple myeloma and primary hyperparathyroidism.
19129688 - Jak2v617f-positive essential thrombocythemia and multiple myeloma with igh/ccnd1 gene t...
11870468 - Imaging findings in the rare catastrophic variant of the primary antiphospholipid syndr...
16318498 - Forensic aspects of mild brain injury.
11925988 - Characteristics of a cholera outbreak, patterns of vibrio cholerae and antibiotic susce...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  48     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-02-27     Completed Date:  2007-04-20     Revised Date:  2007-11-08    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  England    
Other Details:
Languages:  eng     Pagination:  56-64     Citation Subset:  IM    
Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Diphosphonates / adverse effects*,  therapeutic use
Jaw Diseases / chemically induced*,  epidemiology
Middle Aged
Models, Biological
Multiple Myeloma / drug therapy*
Osteonecrosis / chemically induced*,  epidemiology
Retrospective Studies
Reg. No./Substance:
Comment In:
Leuk Lymphoma. 2007 Sep;48(9):1852-4   [PMID:  17786724 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in pati...
Next Document:  Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years...